Bristol-Myers Squibb to Partner with WuXi PharmaTech

Bristol-Myers Squibb announced a strategic partnership with WuXi PharmaTech that will conduct stability studies of new small-molecule drugs from around the world. WuXi will build and operate a dedicated facility in Shanghai for the operation. The facility will be a fully cGMP-compliant 25,000-square-foot analytical testing facility that stores and tests stability samples along with other services for BMS. Financial details of the major new partnership were not disclosed. More details.... Stock Symbol: (NYSE: BMY)  (NYSE: WX)     Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});